August 2017 Br J Cardiol 2017;24:97
BJCardio Staff
A new gene therapy that targets the heart and requires only one treatment session, has been found safe for patients with coronary artery disease, according to a successful trial carried out in Finland (doi: 10.1093/eurheartj/ehx352). The treatment enhances circulation in ischaemic heart muscle and the effects were still visible one year after treatment. The randomised, blinded, placebo-controlled phase 1/2a trial was carried out in collaboration between the University of Eastern Finland, Kuopio University Hospital and Turku PET Centre. The biological bypass is based on gene transfer in which a natural human growth factor, AdVEGF-DΔNΔC, a ne
November 2005 Br J Cardiol (Acute Interv Cardiol) 2005;12:AIC 92–AIC 97
Lucy Blows, Divaka Perera, Simon Redwood
No content available
February 2003 Br J Cardiol (Acute Interv Cardiol) 2003;10(1):AIC 17–AIC 20
Narbeh Melikian, Farzin Fath-Ordoubadi
No content available
May 2002 Br J Cardiol 2002;9:294-6
Matthew J Banks, Jane Flint, Peter R Forsey, George D Kitas
No content available
May 2002 Br J Cardiol 2002;9:251-4
Elliot J Smith, Nicholas P Curzen
No content available
February 2002 Br J Cardiol 2002;9:68-71
Prithwish Banerjee
No content available
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits